MAR 19, 2019 11:23 AM PDT

Efficacy of Cancer Therapeutics is Better When Muscle Mass is Normal

WRITTEN BY: Carmen Leitch

People have been pumping iron to improve their physique for many years, and it’s known that exercise is related to good health. Now scientists have determined that increasing muscle mass could be a life-saver. Researchers at Osaka University found that the loss of skeletal muscles, also known as sarcopenia, is closely related to a lack of responsiveness to therapeutics aimed at advanced non-small cell lung cancer (NSCLC). The findings have been published in Scientific Reports, and are briefly summarized in the video.

Treatments for NSCLC are called programmed cell death (PD-1) inhibitors; they are a relatively new class of drugs that have the potential to combat various types of cancer. They are designed to enhance a patient’s ability to use their own immune system to attack cancer, and as such, depend heavily on the proper function of that patient’s immune system.

Unfortunately, only a small number of patients respond well to these drugs. The Osaka researchers are hopeful that their work will help address this problem. 

“Sarcopenia is a well-known risk factor associated with poor outcomes for several cancer types," said the lead author of the report, Takayuki Shiroyama. "Because muscle degradation is associated with a dysregulated immune response, we wanted to investigate how, in lung cancer patients, sarcopenia impacts the efficacy of PD-1 inhibitor therapy.”

Two lung cancer patients - cross-section of the psoas major muscle (green); non-sarcopenic (left), sarcopenic (right) / Credit: Osaka University

In this study, the scientists assessed the medical records of 42 advanced NSCLC patients who had also been checked for muscle mass to see how well they responded to PD-1 inhibitors. 

“The results were surprisingly emphatic. We found that the treatment outcomes for patients with sarcopenia at the start of therapy were far worse than those without,” revealed the senior author of the work Atsushi Kumanogoh.

The researchers determined that one year after treatment, 38.1 percent of non-sarcopenia patients were in remission but only 10.1 percent of sarcopenia patients had no progression in tumor growth in that same time period.  

“Our findings suggest that baseline skeletal muscle mass has a substantial impact on PD-1 inhibitor efficacy. As such, skeletal muscle mass might be useful for predicting whether treatment is likely to be effective,” explained Shiroyama.

Muscle wasting is commonly observed in patients who have advanced cancer. Some new drugs may help increase skeletal muscle mass, which could be very important to the success of therapeutics.

Patients that will be receiving PD-1 inhibitor therapy may also increase the likelihood that the treatment will be successful if they aim to increase muscle mass before treatment begins.

 

Sources: AAAS/Eurekalert! Via Osaka University, Scientific Reports

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUL 27, 2020
Clinical & Molecular DX
Guidance for Optimization of a Real-Time qPCR Assay
JUL 27, 2020
Guidance for Optimization of a Real-Time qPCR Assay
Optimizing the formulation of reagents for your qPCR assay requires careful experimental design that looks across severa ...
AUG 19, 2020
Immunology
Cancer Mutation Improves Chemo Drug Performance
AUG 19, 2020
Cancer Mutation Improves Chemo Drug Performance
When it comes to cancer biomarkers, it’s often the genetic signatures that are associated with poor patient outcom ...
AUG 22, 2020
Cell & Molecular Biology
A New Way to Describe Enzyme Kinetics
AUG 22, 2020
A New Way to Describe Enzyme Kinetics
The  Michaelis-Menten equation is classic, but it may not be sufficient to describe all enzymatic reactions, new wo ...
AUG 27, 2020
Microbiology
Underground Microbes Use an Ancient Form of Energy Production
AUG 27, 2020
Underground Microbes Use an Ancient Form of Energy Production
Organisms rely on a biological fuel known as ATP, which provides the energy for many processes. In cellular respiration, ...
SEP 01, 2020
Cardiology
Can the Protein Dysferlin Protect Your Heart from Reperfusion Injury
SEP 01, 2020
Can the Protein Dysferlin Protect Your Heart from Reperfusion Injury
Have you ever experienced the head rush you get from standing up to fast? Well, oddly enough, something similar happens ...
SEP 08, 2020
Immunology
Regular Opioid Users Are More Sensitive to Pain, Immune System to Blame
SEP 08, 2020
Regular Opioid Users Are More Sensitive to Pain, Immune System to Blame
Opioids are painkillers such as oxycodone (OxyContin and Percocet) and hydrocodone (Vicodin) that are synthesized to mim ...
Loading Comments...